Evidence map›Paper›PMID 39232707›Full record

ArticleBMC cancer2024

Examining the evolving landscape of liver cancer burden in the United States from 1990 to 2019.

Omar Al Ta'ani, Yazan Al-Ajlouni, Balaji Jagdish, Himsikhar Khataniar, Wesam Aleyadeh, Farah Al-Bitar, Tavankit Singh

Abstract read
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. [Analysis of epidemiological trends from 1990 to 2021 of liver cancer in China].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Omar Al Ta'aniAllegheny Health Network, 320 E North Ave, Pittsburgh, PA, 15212, USA. otaani19@gmail.com.
Yazan Al-AjlouniSchool of Medicine, New York Medical College, NYC, NY, USA.
Balaji JagdishAllegheny Health Network, 320 E North Ave, Pittsburgh, PA, 15212, USA.
Himsikhar KhataniarAllegheny Health Network, 320 E North Ave, Pittsburgh, PA, 15212, USA.
Wesam AleyadehCleveland Clinic Akron General, Akron, OH, USA.
Farah Al-BitarWestern Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.
Tavankit SinghAllegheny Health Network, 320 E North Ave, Pittsburgh, PA, 15212, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLiver cancer (LC) is frequently preceded by cirrhosis and poses a significant public health challenge in the United States (US). Recent decades have seen notable shifts in the epidemiological patterns of LC, yet national data guiding the optimal allocation of resources and preventive efforts remain limited. This study aims to investigate the current trends, risk factors, and outcomes of LC in the US.

methodsThis study utilized the Global Burden of Disease (GBD) dataset to collect data on the annual incident cases, deaths, Disability-Adjusted Life Years (DALYs), age-standardized incidence rates (ASIR), age-standardized death rates, and age-standardized DALY rates of primary LC and its etiologies and risk factors, between 1990 and 2019. Percentage changes in incident cases, DALYs, and deaths and the estimated annual percentage change (EAPC) in ASIR and deaths rates of LC were calculated to conduct temporal analysis. Linear regression was applied for the calculation of EAPCs. Correlations of EAPC with socio-demographic index (SDI) were separately evaluated by Pearson correlation analyses.

resultsWe observed a marked increase in the ASIR of LC, increasing from 2.22 (95% CI: 2.15-2.27) per 100,000 people in 1990 to 5.23 (95% CI: 4.28-6.29) per 100,000 people in 2019, a percentage change of 135.4%. LC due to hepatitis C followed by alcohol use were the primary factors driving this increase. The ASIR and age-standardized death rates of LC showed a significant average annual increase of 3.0% (95% CI: 2.7-3.2) and 2.6% (95% CI: 2.5-2.8), respectively. There was a significant negative correlation between the SDI and the EAPC in ASIR (ρ = -0.40, p = 0.004) and age-standardized death rates (ρ = -0.46, p < 0.001). In 2019, drug and alcohol use, followed by elevated body mass index (BMI) were the primary risk factors for age-standardized DALY rates attributable to LC.

conclusionThe increased burden of LC in the US highlights the need for interventions. This is particularly important given that LC is mostly influenced by modifiable risk factors, such as drug and alcohol use, and elevated BMI. Our findings highlight the urgent need for public health interventions targeting socio-economic, lifestyle, and modifiable risk factors to mitigate the escalating burden of LC.

Indexed as

Liver NeoplasmsAdultAgedCost of IllnessDisability-Adjusted Life YearsFemaleGlobal Burden of DiseaseHumansIncidenceMaleMiddle AgedQuality-Adjusted Life YearsRisk FactorsUnited StatesAlcohol useBurden of diseaseDALYsHepatitis BHepatitis CHepatocellular carcinomaRisk factorsUnited States

Identifiers

PMID39232707
PMCPMC11373298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.